Literature DB >> 3227961

Prospective studies on a lithium cohort. 1. General features.

P Vestergaard1, M Schou.   

Abstract

Since 1979, patients started on long-term lithium treatment at the Psychiatric Hospital in Risskov have been followed systematically with recording of clinical and laboratory variables before the start of treatment, after 6 and 12 months of treatment, and thereafter at yearly intervals. By June 1987, 480 examinations had been carried out before the start of lithium treatment, 236 after treatment for 6 months, and decreasing numbers up to 7 years of lithium treatment. The total lithium exposure time was 548 years. The mean lithium dose was 23.2 mmol/d and the mean serum lithium concentration 0.68 mmol/l. These values are about 30% lower than the corresponding values in patients given lithium treatment prior to 1979. About one half of the patients who had gone through the pre-lithium examinations did not reach the 6-month examination. This was because they did not start lithium, or because they stopped it again before 6 months of treatment or before they had reached that point. Thereafter there was a drop-out rate of about 25% per year during the first 2 years of lithium treatment and about 10% per year after 4-5 years of treatment. More men than women left the cohort.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3227961     DOI: 10.1111/j.1600-0447.1988.tb06361.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  10 in total

1.  Serum amylase in patients treated with lithium.

Authors:  A Tham; L Johnson; A A Mathé
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Seasonality, smoking and history of poor treatment compliance are strong predictors of dropout in a naturalistic 6 year follow-up of bipolar patients.

Authors:  Elena Ezquiaga; Aurelio García-López; Consuelo de Dios; Jose Luis Agud; David Albillo; Lorena Vega-Piris
Journal:  Psychiatr Q       Date:  2014-12

Review 3.  Serum lithium monitoring of prophylactic treatment. Critical review and updated recommendations.

Authors:  M Schou
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

4.  Multi-level regulation of PKCδI alternative splicing by lithium chloride.

Authors:  Deena Bader; Rekha S Patel; Ashley Lui; Chetna Thawani; Rea Rupani; Gitanjali Vidyarthi; Niketa A Patel
Journal:  Mol Cell Biol       Date:  2020-12-07       Impact factor: 4.272

5.  Long-term outcome of lithium prophylaxis in patients initially classified as complete responders.

Authors:  M Maj; R Pirozzi; D Kemali
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Functional genetic variation in the Rev-Erbα pathway and lithium response in the treatment of bipolar disorder.

Authors:  M J McCarthy; C M Nievergelt; T Shekhtman; D F Kripke; D K Welsh; J R Kelsoe
Journal:  Genes Brain Behav       Date:  2011-09-02       Impact factor: 3.449

7.  The effects of centralised and specialised combined pharmacological and psychological intervention compared with decentralised and non-specialised treatment in the early course of severe unipolar and bipolar affective disorders--design of two randomised clinical trials.

Authors:  Lars Vedel Kessing; Hanne Vibe Hansen; Ellen Margrethe Christensen; Henrik Dam; Christian Gluud; Jørn Wetterslev
Journal:  Trials       Date:  2011-02-03       Impact factor: 2.279

8.  Daily electronic self-monitoring of subjective and objective symptoms in bipolar disorder--the MONARCA trial protocol (MONitoring, treAtment and pRediCtion of bipolAr disorder episodes): a randomised controlled single-blind trial.

Authors:  Maria Faurholt-Jepsen; Maj Vinberg; Ellen Margrethe Christensen; Mads Frost; Jakob Bardram; Lars Vedel Kessing
Journal:  BMJ Open       Date:  2013-07-24       Impact factor: 2.692

9.  Stability of lithium treatment in bipolar disorder - long-term follow-up of 346 patients.

Authors:  Anne Berghöfer; Martin Alda; Mazda Adli; Christopher Baethge; Michael Bauer; Tom Bschor; Paul Grof; Bruno Müller-Oerlinghausen; Janusz K Rybakowski; Alexandra Suwalska; Andrea Pfennig
Journal:  Int J Bipolar Disord       Date:  2013-07-31

10.  Daily electronic monitoring of subjective and objective measures of illness activity in bipolar disorder using smartphones--the MONARCA II trial protocol: a randomized controlled single-blind parallel-group trial.

Authors:  Maria Faurholt-Jepsen; Maj Vinberg; Mads Frost; Ellen Margrethe Christensen; Jakob Bardram; Lars Vedel Kessing
Journal:  BMC Psychiatry       Date:  2014-11-25       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.